Pharmtek CG Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowo-akcyjna (KRS 0000446147, NIP 6112729040) is a Polish company, headquartered in Jelenia Góra, Dolnośląskie voivodeship. Pharmtek CG Spółka z Ograniczoną Odpowiedzialnością operates in: Business and other management consultancy activities (PKD 70.22.Z). Industry: Consulting and management. The company has been listed in the National Court Register since January 3, 2013.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Pharmtek CG
Identity
- Name
- Pharmtek CG Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowo-akcyjna
- Legal form
- SPÓŁKA KOMANDYTOWO-AKCYJNA
- Founded
- January 3, 2013
- Registry status as of
- November 21, 2025
- Latest entry
- April 9, 2024
- Founding act
- AKT NOTARIALNY Z DNIA 19.11.2012 R. SPORZĄDZONY PRZED NOTARIUSZEM PRZEMYSŁAWEM SZOCIŃSKIM Z KANCELARII NOTARIALNEJ W JEL…
Articles of association history (1)
- November 19, 2012: AKT NOTARIALNY Z DNIA 19.11.2012 R. SPORZĄDZONY PRZED NOTARIUSZEM PRZEMYSŁAWEM SZOCIŃSKIM Z KANCELARII NOTARIALNEJ W JELENIEJ GÓRZE, REP. A NR 5812/2012
Activities
Other activities
Address and contact
- Address
- KROŚNIEŃSKA, 13A, 58-500, JELENIA GÓRA, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- M. JELENIA GÓRA
- ROBERTRZEM@GMAIL.COM
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 50.8879, 15.7167approx.
Operational status - Pharmtek CG
Founded
January 3, 2013
13 years in operation
Legal form
SPÓŁKA KOMANDYTOWO-AKCYJNA
Registry: RejP
Headquarters
JELENIA GÓRA
DOLNOŚLĄSKIE
Primary PKD
70.22.Z
Business and other management consultancy activities
Share capital
50.0 K PLN
Shareholders
1
shareholder
Board
N/A
Filed years
N/A
Registry entries
16
latest: April 9, 2024
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Pharmtek CG.
No ratings
Related articles
News
MLP Group 2026: net profit of PLN 459m (+23% YoY), a record 370,941 sqm leased and the first dividend policy since 2019
Pruszków-based MLP Group S.A. (KRS 0000053299), a developer and operator of logistics-warehouse parks in Poland, Germany, Austria, Romania and the Netherlands, closed 2025 with net profit of PLN 459.0m (+23.3% YoY vs PLN 372.2m) and EBIT of PLN 701.7m (+29.2%). Rental revenue reached PLN 238.4m (+10%) and property-management services PLN 182.1m (+15.5%). 2025 leasing volume: a record 370,941 sqm (new leases and renewals). EPS PLN 19.13 (+23.3%), equity PLN 3,197m (+16.4%), assets PLN 6.99bn. After a seven-year break, the company has announced a dividend policy for 2026. 2026 targets: +20–30% revenue growth, around 250,000–300,000 sqm of new buildings, 60% of capex allocated to Germany.
News
Murapol 2026: a PLN 4.90 per-share dividend (~11.9% yield) – the highest among WSE developers, net profit of PLN 236m
Bielsko-Biała-based Murapol S.A. (KRS 0000275523), a residential developer with projects in more than 8 Polish cities, posted 2025 net profit of PLN 236m (-2.5% YoY), revenue of PLN 1.26bn (-5.2%) and a gross sales margin of 36.5% (vs 32.4%, +4 pp). Operating cash flow jumped to PLN 311m (vs PLN 100m, roughly threefold). Net sales: 2,856 apartments (-2%), with 2,650 units handed over (-9%). For 2026 the company expects around 3,000 handovers; Q1 2026 sales reached 735 apartments (+4% YoY). The dividend for 2025 totals PLN 4.90 per share (a PLN 2.94 advance in December 2025 plus a PLN 1.97 tranche), for a yield of ~11.9% – the highest in the WSE developer sector.
